Barclays Analysts Give Revance Therapeutics (RVNC) a $40.00 Price Target

Barclays set a $40.00 price target on Revance Therapeutics (NASDAQ:RVNC) in a research note released on Tuesday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research firms have also commented on RVNC. Zacks Investment Research upgraded Revance Therapeutics from a hold rating to a buy rating and set a $26.00 price target on the stock in a research report on Wednesday, August 30th. ValuEngine lowered Revance Therapeutics from a hold rating to a sell rating in a research report on Monday, December 4th. Cantor Fitzgerald reiterated a buy rating and issued a $50.00 price target on shares of Revance Therapeutics in a research report on Tuesday, September 26th. Piper Jaffray Companies upped their price target on Revance Therapeutics from $28.00 to $51.00 and gave the company an overweight rating in a research report on Tuesday, December 5th. Finally, Mizuho boosted their price objective on Revance Therapeutics from $37.00 to $54.00 and gave the company a buy rating in a research note on Wednesday, December 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $43.11.

Shares of Revance Therapeutics (RVNC) traded up $0.95 on Tuesday, hitting $36.20. The stock had a trading volume of 405,100 shares, compared to its average volume of 256,376. Revance Therapeutics has a one year low of $18.00 and a one year high of $37.20.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.06). Revance Therapeutics had a negative return on equity of 67.85% and a negative net margin of 37,161.00%. The firm had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.05 million. During the same quarter in the prior year, the firm earned ($0.64) EPS. The company’s revenue was up .0% on a year-over-year basis. sell-side analysts expect that Revance Therapeutics will post -3.73 earnings per share for the current year.

In other news, CEO L Daniel Browne sold 7,600 shares of the stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $24.94, for a total value of $189,544.00. Following the completion of the sale, the chief executive officer now directly owns 133,188 shares of the company’s stock, valued at $3,321,708.72. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Lauren P. Silvernail sold 11,164 shares of the stock in a transaction that occurred on Thursday, October 12th. The stock was sold at an average price of $26.67, for a total value of $297,743.88. The disclosure for this sale can be found here. Over the last three months, insiders sold 36,426 shares of company stock valued at $956,026. Company insiders own 18.86% of the company’s stock.

Several institutional investors have recently modified their holdings of RVNC. JPMorgan Chase & Co. grew its holdings in shares of Revance Therapeutics by 4.8% in the second quarter. JPMorgan Chase & Co. now owns 3,626,603 shares of the biopharmaceutical company’s stock valued at $95,743,000 after acquiring an additional 166,759 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Revance Therapeutics by 13.1% in the second quarter. Franklin Resources Inc. now owns 3,375,238 shares of the biopharmaceutical company’s stock valued at $89,106,000 after acquiring an additional 391,638 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Revance Therapeutics by 14.4% in the second quarter. Bank of New York Mellon Corp now owns 2,079,562 shares of the biopharmaceutical company’s stock valued at $54,901,000 after acquiring an additional 261,764 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Revance Therapeutics by 7.3% in the second quarter. Vanguard Group Inc. now owns 931,623 shares of the biopharmaceutical company’s stock valued at $24,595,000 after acquiring an additional 63,505 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of Revance Therapeutics by 0.6% in the second quarter. State Street Corp now owns 452,490 shares of the biopharmaceutical company’s stock valued at $11,944,000 after acquiring an additional 2,637 shares in the last quarter. 76.69% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This story was posted by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.com-unik.info/2017/12/22/barclays-analysts-give-revance-therapeutics-rvnc-a-40-00-price-target.html.

About Revance Therapeutics

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit